Last reviewed 2026-04-23 · How we verify

LRG-002

LRG-002 is a monoclonal antibody that targets the PD-1 receptor.

LRG-002 is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.

At a glance

Mechanism of action

By binding to PD-1, LRG-002 prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively.

Approved indications

• Non-small cell lung cancer, PD-L1 positive
• Head and neck squamous cell carcinoma

Common side effects

• Pneumonitis
• Hypothyroidism
• Hyperthyroidism
• Fatigue
• Diarrhea
• Nausea
• Vomiting
• Abdominal pain
• Muscle pain
• Arthralgia

Key clinical trials

• Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• LRG-002 CI brief — competitive landscape report
• LRG-002 updates RSS · CI watch RSS
• Sandoz portfolio CI